{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T02:53:10Z","timestamp":1793847190200,"version":"4.6.1"},"reference-count":17,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":701,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharmacology"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1002\/jcph.162","type":"journal-article","created":{"date-parts":[[2013,10,12]],"date-time":"2013-10-12T01:26:02Z","timestamp":1381541162000},"page":"1240-1251","source":"Crossref","is-referenced-by-count":39,"title":["Pharmacokinetic and pharmacodynamic properties of canakinumab in patients with gouty arthritis"],"prefix":"10.1002","volume":"53","author":[{"given":"Abhijit","family":"Chakraborty","sequence":"first","affiliation":[{"name":"Clinical Pharmacology; Novartis Pharmaceuticals Corporation; East Hanover NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linh M.","family":"Van","sequence":"additional","affiliation":[{"name":"Advanced Quantitative Sciences; Novartis Institute for Biomedical Research; Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrej","family":"Skerjanec","sequence":"additional","affiliation":[{"name":"Biologics & Safety Disposition; Novartis Institute for Biomedical Research; Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Floch","sequence":"additional","affiliation":[{"name":"Biologics & Safety Disposition; Novartis Institute for Biomedical Research; Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf R.","family":"Klein","sequence":"additional","affiliation":[{"name":"Biologics & Safety Disposition; Novartis Institute for Biomedical Research; Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Krammer","sequence":"additional","affiliation":[{"name":"Clinical Development Unit, Department of Integrated Hospital Care Franchise; Novartis Pharma AG; Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gangadhar","family":"Sunkara","sequence":"additional","affiliation":[{"name":"Clinical PK\/PD, Drug Metabolism and Pharmacokinetics; Novartis Institutes for Biomedical Research; East Hanover NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Howard","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology; Novartis Pharmaceuticals Corporation; East Hanover NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,9,30]]},"reference":[{"issue":"10","key":"10.1002\/jcph.162-BIB0001|jcph162-cit-0001","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1002\/art.22938","article-title":"The role of interleukin-1 and the inflammasome in gout: implications for therapy","volume":"56","author":"Pope","year":"2007","journal-title":"Arthritis Rheum."},{"issue":"5","key":"10.1002\/jcph.162-BIB0002|jcph162-cit-0002","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/ar2509","article-title":"Developments in the scientific and clinical understanding of gout","volume":"10","author":"So","year":"2008","journal-title":"Arthritis Res Ther."},{"issue":"12","key":"10.1002\/jcph.162-BIB0003|jcph162-cit-0003","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1111\/j.1469-0691.2011.03677.x","article-title":"Immunosuppressive monoclonal antibodies: current and next generation","volume":"17","author":"Focosi","year":"2011","journal-title":"Clin Microbiol Infect."},{"key":"10.1002\/jcph.162-BIB0004|jcph162-cit-0004","volume-title":"Ilaris (canakinumab) injection for subcutaneous use [prescribing information]","author":"Novartis Pharmaceuticals Corporation","year":"2012"},{"issue":"25","key":"10.1002\/jcph.162-BIB0005|jcph162-cit-0005","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis","volume":"367","author":"Ruperto","year":"2012","journal-title":"N Engl J Med."},{"issue":"10","key":"10.1002\/jcph.162-BIB0006|jcph162-cit-0006","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1002\/art.27600","article-title":"Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study","volume":"62","author":"So","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1002\/jcph.162-BIB0007|jcph162-cit-0007","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1186\/ar3297","article-title":"Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat gouty arthritis by suppressing inflammation: results of a randomized, dose-ranging study","volume":"13","author":"Schlesinger","year":"2011","journal-title":"Arthritis Res Ther."},{"issue":"11","key":"10.1002\/jcph.162-BIB0008|jcph162-cit-0008","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1136\/annrheumdis-2011-200908","article-title":"Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions","volume":"71","author":"Schlesinger","year":"2012","journal-title":"Ann Rheum Dis."},{"issue":"6","key":"10.1002\/jcph.162-BIB0009|jcph162-cit-0009","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11599820-000000000-00000","article-title":"Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1\u03b2 monoclonal antibody","volume":"51","author":"Chakraborty","year":"2012","journal-title":"Clin Pharmacokinet."},{"issue":"3","key":"10.1002\/jcph.162-BIB0010|jcph162-cit-0010","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/art.1780200320","article-title":"Preliminary criteria for the classification of the acute arthritis of primary gout","volume":"20","author":"Wallace","year":"1977","journal-title":"Arthritis Rheum."},{"issue":"1-2","key":"10.1002\/jcph.162-BIB0011|jcph162-cit-0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2004.06.002","article-title":"Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products","volume":"289","author":"Mire-Sluis","year":"2004","journal-title":"J Immunol Methods."},{"issue":"5","key":"10.1002\/jcph.162-BIB0012|jcph162-cit-0012","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jpba.2008.09.020","article-title":"Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products","volume":"48","author":"Shankar","year":"2008","journal-title":"J Pharm Biomed Anal."},{"key":"10.1002\/jcph.162-BIB0013|jcph162-cit-0013","volume-title":"NONMEM users guide (Version VI)","author":"Beal","year":"2009"},{"issue":"5","key":"10.1002\/jcph.162-BIB0014|jcph162-cit-0014","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1365-2125.2006.02803.x","article-title":"A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab","volume":"63","author":"Hayashi","year":"2007","journal-title":"Br J Clin Pharmacol."},{"key":"10.1002\/jcph.162-BIB0015|jcph162-cit-0015","doi-asserted-by":"crossref","first-page":"54S","DOI":"10.1177\/0091270011413894","article-title":"Characterizing the impact of renal impairment on the clinical pharmacology of biologics","volume":"52","author":"Meibohm","year":"2012","journal-title":"J Clin Pharmacol."},{"key":"10.1002\/jcph.162-BIB0016|jcph162-cit-0016","unstructured":"http:\/\/www.fda.gov\/downloads\/Drugs\/.\/Guidances\/UCM204959.pdf"},{"issue":"12","key":"10.1002\/jcph.162-BIB0017|jcph162-cit-0017","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1136\/ard.2011.152728","article-title":"Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes","volume":"70","author":"Kuemmerle-Deschner","year":"2011","journal-title":"Ann Rheum Dis."}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.162","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/jcph.162","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T13:02:53Z","timestamp":1657803773000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jcph.162"}},"subtitle":["The Journal of Clinical Pharmacology"],"short-title":[],"issued":{"date-parts":[[2013,9,30]]},"references-count":17,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"URL":"https:\/\/doi.org\/10.1002\/jcph.162","relation":{},"ISSN":["0091-2700"],"issn-type":[{"value":"0091-2700","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9,30]]}}}